Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences files regular SEC disclosures that document its clinical development activities, financial position, and material corporate events. For a clinical-stage biopharmaceutical company, these filings reveal how the business allocates capital across research programs, the progress of drug candidates through development stages, and the company's runway for continued operations.
The company's 10-K annual reports and 10-Q quarterly filings provide detailed breakdowns of research and development expenses by program, cash reserves, and clinical trial timelines. These documents explain which drug candidates are in active development, the design of ongoing clinical trials, and the company's strategy for advancing its endocannabinoid-targeted therapeutics toward regulatory approval. For biotech companies, the Management Discussion and Analysis section often contains crucial details about trial enrollment rates, expected data readout timelines, and capital requirements for completing development milestones.
Form 8-K filings from Artelo announce material events including clinical trial results, financing transactions, partnership agreements, and regulatory interactions. These real-time disclosures provide immediate notification when the company announces public equity offerings, completes private placements, or reports significant clinical data. For investors tracking clinical-stage biotech stocks, 8-K filings often contain the most time-sensitive information affecting valuation.
Proxy statements (DEF 14A) reveal executive compensation structures, which for development-stage companies typically include significant stock-based components tied to achieving clinical and regulatory milestones. Form 4 insider transaction filings show when executives and directors buy or sell shares, potentially signaling confidence levels in upcoming clinical readouts or corporate developments.
Our platform provides AI-powered summaries that highlight key disclosures within these technical documents, making it easier to identify changes in cash burn rates, clinical trial progress, and strategic direction without reading through extensive regulatory filings.
Daniel S. Farb reported on Schedule 13D/A that he directly owns 153,003 shares of Artelo Biosciences, representing approximately 7.7% of outstanding common stock based on an outstanding share count that includes 1,555,493 shares reported September 16, 2025 and 441,210 shares issued in an underwritten offering on October 1, 2025. Farb paid approximately $850,036 in personal funds for the 153,003 shares and also holds 11,299 warrants exercisable at $10.00 per share that expire in June 2030. Those $10 warrants are subject to a beneficial ownership limitation currently set at 4.99%, so Farb cannot exercise the warrants to increase his stake above that limit absent notice to the issuer. Farb also confirmed delivery of the remaining 3 shares underlying previously held $5.82 warrants and no longer holds those warrants.
ArteLo Biosciences, Inc. (ARTL) is offering an aggregate of 454,545 shares of common stock and associated Pre-funded Warrants. The Pre-funded Warrants have an exercise price of $0.001 per share and are immediately exercisable upon issuance until exercised in full. The prospectus supplement also notes Ordinary Shares that will be issuable upon exercise of those Pre-funded Warrants. Separately, the filing includes a brief scientific description that the CB1 receptor is distributed in brain regions tied to motor control, emotion, motivated behavior and energy homeostasis while the CB2 receptor is mainly expressed in the immune system and upregulated in response to tissue stress or damage.
Daniel S. Farb filed a Schedule 13D disclosing a 9.8% direct stake in Artelo Biosciences, Inc. (symbol ATLEW), owning 153,000 shares purchased with personal funds for approximately $850,019. Farb also acquired warrants under a June 2025 Securities Purchase Agreement: 11,299 $10 warrants and 22,598 $5.82 warrants22,595 shares; the issuer declined delivery of 3 shares and intends to pay $17.46 for those undelivered shares. Farb delivered a director nomination letter naming himself and Scott D. Pomfret and entered a Joint Filing and Solicitation Agreement with Pomfret; Pomfret granted Farb a power of attorney to assist with the proxy solicitation. The registered resale of the SPA securities was filed on Form S-1.
Artelo Biosciences, Inc. amended its bylaws to change several shareholder governance provisions. The amendments modify the required notice period for Board special meetings, eliminate the right of stockholders to take action without a meeting, and state that the Company will be treated as an "issuing corporation" under Nevada statutes regardless of its number of record stockholders or whether it does business in Nevada.
The bylaws also set the record date for determining shareholders entitled to notice, to vote, or to receive dividends or distributions at not more than 60 days prior to the relevant action. These are procedural and corporate governance changes reflected in the filing.
Artelo Biosciences' prospectus supplement describes terms for issuing debt securities, warrants and units and the broad rights, remedies and amendment limits under the indenture. It discloses that the company currently receives UK R&D tax credits for clinical trials but expects such credits to be unavailable for expenditures outside the UK with effect from April 2024. The filing states the company will need additional financing to pursue its business objectives and acknowledges failure to obtain financing could materially impair operations. Detailed provisions cover designation, pricing, interest, currency, redemption, default events and amendment/consent thresholds for any series of securities.
Artelo Biosciences (ARTL) disclosure describes terms for offering debt securities, warrants and units under an indenture, including extensive customizable features such as interest rates, denominations, currencies, security, covenants, events of default and amendment limitations. The filing states the company needs additional financing and warns operations could be adversely affected if such financing is unavailable. It notes the company currently receives UK R&D tax credits for clinical trials but those credits are not expected to apply to expenditures outside the UK starting April 2024. The supplement also summarizes trustee remedies, defeasance mechanics, and procedural rights for holders relating to defaults and amendments.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
